LETTERS TO THE EDITOR

Behavioural status during the intracarotid amobarbital procedure (Wada test): relevance for surgical management

Presurgical evaluation in many epilepsy programmes often includes the intracarotid amobarbital procedure (IAP). Sodium amytal is injected into the internal carotid artery to produce a temporary “pharmacological paralysis” of hemispheric function. Traditionally, the IAP has been employed in patients with refractory temporal lobe epilepsy being considered for anterior temporal lobectomy. In these cases it is used to determine cerebral dominance for language, to assess the risk of severe postsurgical amnesia, and to predict postsurgical material specific memory changes. More recently, the use of the IAP has been extended to complement EEG localisation and radiological data by lateralisling temporal lobe dysfunction.

A 39 year old man had a 23 year history of severe life threatening epilepsy with a multi-episode status epilepticus. Interictal EEG disclosed a well defined atrophic lesion involving the left frontal lobe, considered likely to be post-traumatic in origin. Interictal FDG PET and HMPAO SPECT disclosed hyperfusion in the left anterior frontal region commensurate with the abnormality shown on MRI. Although his electroclinical pattern was suggestive of symptomatic generalised epilepsy, because of the left frontal lesion, seizure onset from that region was considered likely.

On neuropsychological examination, his general cognitive function was normal. At behavioural level, however, he presented as very peurile in manner with a very rigid, inflexible cognitive style. The neuropsychological opinion was of a mild frontal lobe syndrome consistent with the history of traumatic head injury. There was no current evidence of psychiatric disorder. Although he had been head injured and the possibility of more generalised head injury. There was no current evidence of psychiatric disorder. Although he had been head injured and the possibility of more generalised head injury. There was no current evidence of psychiatric disorder. Although

We report a case of frontal lobe epilepsy secondary to a traumatic head injury. Out of concern for untoward postoperative behavioural change, we employed the IAP in an attempt to predict the risk of a frontal lobe syndrome. A 39 year old man had a 23 year history of severe refractory epilepsy. The seizures postdated a road traffic accident at the age of 12 years when he sustained a head injury with an ill defined period of loss of consciousness. Seizures commenced within months of that injury and, although initially well controlled, became refractory within a few years. The seizures included staring spells, violent tonic-clonic seizures, and tonic drop attacks. He had complications from his epilepsy including a fractured jaw, two episodes of severe burning due to seizures while showering, multiple episodes of postictal confusion and probable postictal psychosynthesis, a lung abscess secondary to aspiration, and episodes of status epilepticus. Interictal EEG revealed bilateral generalised spike and wave discharges at around 2 Hz-2.5 Hz with some mild increase in bilateral slow activity and no convincing evidence of electrographic fociation. Video EEG monitoring showed apparent generalised seizures without any focal onset on scalp EEG. Brain MRI disclosed a well defined atrophic lesion involving the left frontal lobe, considered likely to be post-traumatic in origin.

Despite its underestimated value in many individual cases of temporal lobe epilepsy, the IAP has remained a controversial assessment instrument.1 Amid this controversy its potential usefulness in other patient groups seems to have been overlooked. A primary criticism of its use in temporal lobe epilepsy has been the question of irrigation and whether the medial temporal lobe is adequately “disable” during the procedure. This particular limitation is not applicable to the patient with frontal lobe epilepsy, as the region of interest is clearly ablated via supply from the carotid arterial system. Caution must, however, be exercised with respect to possible crossflow into the contralateral anterior cerebral artery via the anterior communicating artery. When such crossflow is present, the ability to assess validity the integrity of contralateral frontal lobe function will be compromised. The adverse result of this is that the IAP in the use with in cases of temporal lobe epilepsy, only a restricted form of assessment is possible with the frontal lobe patient during the period of ablation. A limitation not withstanding, the IAP does seem most useful.

It should be borne in mind that the degree of frontal lobe dysfunction induced by the IAP probably represents the “worst case” scenario, as the entire frontal lobe is included in the ablation. There are likely to be few surgical scenarios in which a comparable extensive resection of tissue is likely to be considered, and results must be interpreted in this context. This limitation notwithstanding, the IAP does seem to have a role in separating out those patients in whom more extensive frontal lobe resections could be considered opposed to those in whom a more conservative approach is warranted.

This case report forms only the basis for a novel hypothesis that clearly requires more rigorous scientific research before its clinical utility can be reliably established. Nonetheless, we think that it is worth drawing the attention of the epileptological community to the potential application of the IAP in the surgical management of extratemporal cases.

MARIE F O’SHEA
MICHAEL M SALING
Department of Neuropsychology

SAMUEL F BERKOVIC
Department of Neurology, Austin and Repatriation Medical Centre, Melbourne, Australia; and Department of Medicine, University of Melbourne, Grattan Street, Parkville 3052, Australia.

Correspondence to: Dr Marie F O’Shea, Department of Neuropsychology, Austin and Repatriation Medical Centre (Austin Campus), Studley Road, Heidelberg, Victoria 3084, Australia. Telephone 613 3 03 4946 9513; Fax 613 3 03 4945 2654.


J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.67.4.556 on 1 October 1999. Downloaded from http://jnnp.bmj.com/ on April 7, 2022 by guest. Protected by copyright.
Reversal of tetrabenazine induced depression by selective noradrenaline (norepinephrine) reuptake inhibition

Tetrabenazine (TBZ), a synthetic benzoquinolizine, was first introduced as a neuroleptic agent in 1960, and is now widely used in the treatment of hyperkinetic movement disorders such as chorea, tics, or tardive dyskinesia. The side effect profile is mainly characterised by the triad of drowsiness/fatigue, parkinsonism, and depression; depression is found in about 15% of patients treated with TBZ.1 We here report on the rapid reversal of depressive symptoms in a patient treated with TBZ for orofacial dystonia by administering the new and highly selective noradrenaline (norepinephrine) reuptake inhibitor (SNRI) reboxetine.2

On admission, the 64 year old woman presented with perioral and lingual hyperkinesias as well as intermittent and involuntary movements of her lower jaw, which had lasted for about 2 years, causing her a considerable inconvenience in articulation. No history of neuroleptic treatment or Parkinson’s disease was evident. Her cranial CT and blood chemistry were normal. We diagnosed a segmental dystonia, which improved dramatically after a tetrabenazine medication (60 mg a day). This successful treatment response, however, was accompanied by a severe depressive syndrome, which was characterised by a mixed anxiety-depressive mood, low self esteem, a complete loss of drive, and intermittent suicidal ideations. After switching from TBZ to tiapride, the patient recovered from depression, but her neurological status worsened significantly. The re-exposure to TBZ again ameliorated hyperkinesia, but provoked a depressive relapse. A comedication with reboxetine (6 mg/day), a new and selective noradrenaline reuptake inhibitor, finally led to a stable remission of the depressive symptoms within a week, without any worsening of the dystonic syndrome.

Tetrabenazine (TBZ) is known to act as a monoamine depleting and dopamine receptor blocking drug.3 In more detail, TBZ binds to and inhibits specifically the human vesicular monoamine transporter isoform 2 (hVMAT2). Whereas the indolamine serotonin (5-HT) reuptake forms a similar affinity for both hVMAT1 and hVMAT2, catecholamines such as noradrenaline exhibit a threefold higher affinity for hVMAT2.4 As these specific transporters are responsible for packaging monoamine neurotransmitters into presynaptic secretory vesicles for release by exocytosis, the inhibition of hVMAT2 by compounds such as tetrabenazine thus results in consecutive noradrenaline depletion.5

Alterations of noradrenergic neurotransmission—that is, a neuronal noradrenaline depletion—can therefore be postulated to form one major origin of TBZ induced depressive symptoms with this assumption, brain-specific catecholaminergic activity enhancers (CAEs) such as phenylethylamine have been shown to antagonise TBZ induced depression-like behaviour in rats.6 Modulating this altered noradrenergic neurotransmission pattern by the administration of selective noradrenaline reuptake inhibitors such as reboxetine may thus provide a new, specific, and fast acting tool in the management of depression caused by TBZ and related (neuroleptic) compounds.

Spinal sulcal artery syndrome due to spontaneous bilateral vertebral artery dissection

In young adults vertebral artery dissection (VAD) is an important cause of brain infarction.1,2 A known mechanism is microtrauma due to abrupt head movements for example, chiropractic manoeuvres. In addition a pathogenetic role of connective tissue diseases, cystic media necrosis, fibromuscular dysplasia, migraine, and inflammatory diseases has been postulated.3 In VAD initial neck pain is often reported, which may be slight. Lesions caused by VAD are cerebellar or brainstem infarcts, unilateral or bilateral thalamic infarcts (top of the basilar syndrome), or infarctions in the posterior cerebral artery territory due to intra-arterial embolism or haemodynamic decompensation when collaterals are insufficient.4 Lesions of the spinal cord are rare because of its good collateral supply.5 We report on a patient with a syndrome of the spinal sulcal artery (incomplete Brown-Séquard syndrome) caused by spontaneous bilateral VAD. A 43 year old man with a history of arterial hypertension presented with left sided numbness sparing the face, which had evolved suddenly while he was walking. In addition, he reported on dull right sided neck pain irradiating into the occiput, which had been initiated by a head rotation while he was working at a computer 2 weeks before. The neck pain had spontaneously ceased 6 days later. Neurological examination disclosed dissociated sensation defect on the left with an indistinct level around C4 to C6. Below this level on the left he had a marked hypalgesia and nearly a loss of temperature sense. The right limbs were warmer than the left ones. In addition, we found mild right sided motor system deficits. Cranial nerve function was intact, despite a right sided Horner’s syndrome. According to chest radiography phrenic nerve function was preserved. Routine laboratory findings including CSF analysis were normal. The hemiparesis and the different temperature sensation in the limbs resolved completely within 3 weeks.

Tibial nerve somatosensory evoked potentials (SSEPs) had regular N22 and P40 latencies and amplitudes. Central motor conduction time (CMCT) and transcranial magnetic stimulation was prolonged to the right abductor digiti minimi (9.2 ms) and tibialis anterior (23.1 ms). The CMCT to the left target muscles was normal. Duplex sonography showed increased flow velocity on the level of the cervical vertebrae 3 to 5 with a maximum of 214 cm/s in the right and 197 cm/s in the left vertebral artery. Colour flow showed irregular narrowings of the lumen indicating dissections.

Cerebral MRI showed a spinal cord infarction at the level C2 (figure). The circumference and dorsal part of the cord were not affected. In digital subtraction angiography (DSA) both vertebral arteries had string signs in the V1 and V2 segments with collateral flow to the distal V2–4 segments via the threecerebral trunk (cervical ascendent artery) and the costocervical trunk also. The anterior spinal artery was incompletely contrasted by unilateral spinal branches of the right vertebral artery. They originated at the level of dissection. The intradural origins of the anterior spinal artery (C2) and the vertebral arteries (V4 segment) were not visible.

Bilateral spontaneous VAD is not rare, but often missed. In most cases, microtrauma preceding the dissection can be recalled by the patients. Due to the mild mechanical impact, the action of predisposing factors might be postulated. Among these may be changing in type III collagen, migraine, fibromuscular dysplasia, infections in the near past, and inflammatory vasculopathy.6 Magnetic resonance imaging with typical semilunar mural haematoma and in addition magnetic resonance angiography (MRA) with complementary documentation of an intraluminal or tapering occlusion have a high sensitivity and specificity in cases of internal carotid artery dissection.7 By contrast, mural haematoma of the VA especially in the V1 and the V3 segments are often not detectable by MRI. In cases of unclear non-invasive findings, DSA is still the method of choice.8

In addition to consecutive brain infarctions, cervical spinal cord infarctions and nerve root compression syndromes may occur in cases of unilateral or bilateral VAD. Probably as a result of the pial collateral network and the dual posterior spinal artery, spi-
Cerebral cavernous malformations are vascular malformations mostly located in the CNS. Their frequency is estimated close to 0.5% in the general population. Cerebral cavernous malformations occur as a sporadic or hereditary condition. From the Hispanic-American population, familial forms were reported with a high frequency. CCM1, a hitherto unidentified gene mapping on chromosome 7 was shown to be involved in all families with cerebral cavernous malformations of Hispanic-American descent with a strong founder effect. Around 50% of non-Hispanic-American families showed linkage to CCM1 but no common haplotype was found. A recent study showed linkage of cerebral cavernous malformations to two additional loci. No Spanish family with cerebral cavernous malformations has been analysed so far.

We report herein a genetic linkage analysis conducted on nine Spanish families with cerebral cavernous malformations. All procedures were approved by an ethics committee. The families were unrelated and originated from different regions of Spain (south west (CVE2, 3, 4, 10, 17, 25), central (CVE24), south east (CVE28), and north east (CVE29). Seventy-seven subjects including 55 potentially informative meioses and 12 spouses gave their informed consent. They were examined by a board certified neurologist, underwent cerebral MRI, and blood samples were taken. Magnetic resonance imaging was used to establish status for linkage analysis. Thirty-four members had MRI diagnosis of cavernomas and were considered as affected. Among them, 14 experienced neurological symptoms (cerebral haemorrhage n=6, seizures n=8). Nineteen members with normal cerebral MRI were considered as healthy. Twelve members without MRI investigation had an unknown status. Analysis of pedigrees was consistent with an autosomal dominant transmission. The assignment to the autosomal dominant transmission was confirmed by means of informative meioses and the segregation of the disease phenotype within each family. The linkage analysis was performed using the genetic mapping software LINKAGE (Lander and Green, 1987). The logarithm of the odds ratio (LOD score) was calculated for each gene position.

### Table A

<table>
<thead>
<tr>
<th>Marker</th>
<th>Hispanic American</th>
<th>CVE2</th>
<th>CVE3</th>
<th>CVE4</th>
<th>CVE10</th>
<th>CVE24</th>
<th>CVE25</th>
<th>CVE28</th>
<th>CVE17</th>
<th>CVE29</th>
</tr>
</thead>
<tbody>
<tr>
<td>D7S2410</td>
<td>279</td>
<td>273</td>
<td>265</td>
<td>269</td>
<td>265</td>
<td>265</td>
<td>265</td>
<td>265</td>
<td>265</td>
<td>265</td>
</tr>
<tr>
<td>D7S2409</td>
<td>ND</td>
<td>221</td>
<td>219</td>
<td>215</td>
<td>221</td>
<td>219</td>
<td>223</td>
<td>219</td>
<td>223</td>
<td>219</td>
</tr>
<tr>
<td>D7S1813</td>
<td>137</td>
<td>123</td>
<td>127</td>
<td>127</td>
<td>127</td>
<td>125</td>
<td>127</td>
<td>127</td>
<td>127</td>
<td>127</td>
</tr>
<tr>
<td>D7S1789</td>
<td>137</td>
<td>139</td>
<td>133</td>
<td>133</td>
<td>129</td>
<td>129</td>
<td>129</td>
<td>129</td>
<td>129</td>
<td>129</td>
</tr>
<tr>
<td>M655B</td>
<td>ND</td>
<td>135</td>
<td>133</td>
<td>131</td>
<td>133</td>
<td>135</td>
<td>129</td>
<td>129</td>
<td>129</td>
<td>129</td>
</tr>
<tr>
<td>D7S646</td>
<td>185</td>
<td>185</td>
<td>185</td>
<td>187</td>
<td>187</td>
<td>183</td>
<td>185</td>
<td>181</td>
<td>187</td>
<td>197</td>
</tr>
<tr>
<td>D7S558</td>
<td>107</td>
<td>107</td>
<td>107</td>
<td>103</td>
<td>107</td>
<td>103</td>
<td>103</td>
<td>103</td>
<td>103</td>
<td>103</td>
</tr>
<tr>
<td>D7S689</td>
<td>129</td>
<td>127</td>
<td>125</td>
<td>129</td>
<td>127</td>
<td>127</td>
<td>127</td>
<td>127</td>
<td>127</td>
<td>127</td>
</tr>
</tbody>
</table>

(A) Pedigrees of the nine families with cerebral cavernomas. Black symbols=symptomatic patients with cavernous angiomas on MRI; half filled symbols=asymptomatic members with cavernous angiomas on MRI; empty symbols=asymptomatic members with normal MRI; question mark=members with unknown status. (B) Comparison of the Hispanic-American CCM1 haplotype and the haplotypes segregating with the disease phenotype within Spanish families. Polymorphic markers are shown on the left. Numbers indicate the size on base pairs. Primers used to amplify D7S2409 were different from those in the Hispanic-American families resulting in a different size of the amplified fragment. M655B was not studied in the Hispanic-American families. Family CVE24 was not informative for D7S646. For families CVE17 and CVE29, the two haplotypes of the affected siblings are indicated. ND=not determined.
One of the dominant pattern of inheritance (figure A).

Eight polymorphic microsatellite markers spanning the CCM1 interval were selected for linkage analysis. Four were chosen from the Greenfinch linkage map (D7S2410, D7S2409, D7S558, D7S689), and three from the Cooperative Human Linkage Center (D7S1813, D7S1789, D7S558). The last one (M65B) was identified by SL based on sequencing data of a bacterial artificial chromosome (Genbank HSAC0000065; BAC RG085C05). The length of the genetic interval flanked by markers D7S2410 and D7S689 is 4 centimorgans (cM). Marker distances between D7S2410/D7S2409, D7S1813/D7S1789, D7S558, and D7S689 have been estimated to be 2.2 cM, and 1.8 cM, respectively. Oligonucleotide sequences are available through the Genome Data Bank (John Hopkins University, Baltimore). Genotyping and linkage analysis (LINKAGE package version 5.1) were performed as previously described.4

Lod scores were calculated in the five families having a sufficient number of potential meioses—that is, CVE1 (eight), CVE4 (16), CVE7 (seven), CVE25 (five), and CVE28 (seven). Lod scores higher than 1 were obtained for three families (CVE3, 4, and 28) for at least one marker. Despite the limited informativeness of the markers within family CVE4, lod scores did not reach the level of 3. In family CVE10, lod scores were close to 1 for four markers (D7S2410, D7S1789, D7S558, D7S689). Furthermore, CVE10 patients had a lod score close to 0 to 1 for all markers. In this family, two affected and one asymptomatic sibling with normal standard MI inherited the same haplotype from their affected father. When the data of all examined families were pooled, a maximum combined lod score of 5.92 was obtained for marker D7S2410 at θ = 0.

In seven families (CVE2, 3, 4, 10, 24, 25, and 28), all affected members inherited an haplotype that was not shared by their healthy relatives (figure B). In family CVE17, both affected siblings inherited a distinct haplotype from their affected mother. When the data of all examined families were pooled, a maximum combined lod score of 5.92 was obtained for marker D7S2410 at θ = 0.

None of the families shared a common haplotype (figure B). In addition, the extended Hispano-American haplotype was not segregating with the disease phenotype in any of the nine families including the four families with suggested linkage to CCM1. However, two out of nine families (CVE2 and 3), the D7S646 (185bp) and D7S558 (107bp) alleles segregating with the disease phenotype were identical to the ones observed in the Hispano-American haplotype. Consequently, we analysed the frequency of this combination of alleles within a panel of 80 haplotypes of 40 healthy white subjects. Frequency was 17% compared with 29% in our Spanish sample. Therefore, this finding might be attributed to a random distribution of these alleles.

In conclusion, linkage analysis of Spanish families with cerebral cavernous malformations did not show any evidence for Hispano-American haplotype sharing or a founder effect. Although our sample was limited in size and does not therefore normally exclude the possibility of a Hispanic-American haplotype in additional Spanish families with cerebral cavernous malformations, this haplotype is more likely not predominant in Spain, and the strong founder effect seen in all published Hispano-American families with cerebral cavernous malformations might be specific for this population.

HJ is supported by the Schweizerische Stiftung für medizinisch-biologische Stipendien (Switzerland), SL by the Fonds de Recherche en Santé (Canada), PT by the Comité des Enseignants de Neurologie et ZNEMA pharmacutical group. The work was founded by INSERM, Ministère de l'Enseignement Supérieur et de la Recherche, CSIC, and the Fondo de Investigacion de la Seguridad Social (Piss: 990407).

H H JUNG
P LAUBAGE
S LABERGE
E MARECHAL
E TOURNIER-LASSERVE
INSERM U25, Faculté de Médecine Necker, Paris, France
M LUCAS
Laboratorio de Biologia Molecular
J M GARCIA-MORENO
M A GAMERO
G IZQUIERDO
Servicio de Neurología, Hospital Universitario Virgen Macarena, Avenida Dr Fedriani, 41071 Sevilla, Spain
E TOURNIER-LASSERVE
Hôpital Lariboisière, Paris, France

Correspondence to: E.Tournier-Lasserve, INSERM U25, Faculté de Médecine Necker, 156 Rue de Vaugirard, 75015 Paris, France. Telephone 0033 1 45 67 25 97; fax 0033 1 40 56 01 07; email: turnier@necker.fr


Hydrocephalus caused by metastatic brain lesions: treatment by third ventriculostomy

Metastasis to the brain occurs in 20%–40% of cancer patients.1 About 20% of these metastases are located in the posterior fossa, cerebellum, and brainstem. Metastatic disease to the ventricles can obstruct the flow of cerebrospinal fluid (CSF) producing in the ventricles to the subarachnoid space where it is normally absorbed by arachnoid granulations. This typically causes an obstructive or non-communication hydrocephalus. A ventriculostomy is customarily placed to drain CSF from a lateral ventricle through a pressure regulating valve and into the atrium or peritoneal or pleural cavity. Even though this technique has been successful in relieving the hydrocephalus, it has about a 50% chance of infection or failure from blockage.1

Another option for the treatment of obstructive hydrocephalus is third ventriculostomy, a minimal invasive endoscopic neu- rosurgical procedure. In performing third ventriculostomy, a hole is created in the floor of the third ventricle, allowing CSF inside the ventricle to drain out to the CSF space surrounding the brain. Although third ventriculostomy has a low operative morbidity and high probability success in obstructive hydrocephalus, it is only commonly used on patients with aqueductal stenosis and the pediatric population. To avoid placing shunts in patients with inoperable metastatic brain tumours who typically have only a few months to live, we have offered the patients third ventriculostomy as a palliative procedure.

We performed third ventriculostomy on seven patients with hydrocephalus caused by metastatic tumours of the posterior fossa or thalamus. They typically presented with symptoms of acute hydrocephalus in addition to any local mass effect of the tumour. Postoperatively, five patients were relieved of hydrocephalic symptoms and follow up brain imaging studies disclosed decreased ventricu- lar size. These five patients had a median hospital time of 6.5 days and median survival of 59 days after the operation. Our hospital stay was prolonged by care of their primary disease. However, most of our patients who underwent this operation for hydrocephalus caused by other diseases were discharged from the hospital after 3–4 days and 48 hours from the procedure. There were no operative complications. All five patients had no evidence of redevelopment of hydrocephalus up to the last clinic visit.

These results were successful outcomes from their third ventriculostomy. One patient (case 4) showed no change from his initial neurological exam after the procedure, but his mental status deteriorated on post opera- tive day 6. Brain CT showed no change in the size of his ventricles compared with the scan obtained on the day of admission. The patient's family requested comfort care only and the patient died 2 days later. In the second case (case 6) the patient had improve- ment in his neurological examination and ventricle size by CT scan immediately after the operation, but had recurrent symptoms of hydrocephalus 11 days later. After placement of a ventriculoperitoneal shunt, his examination returned to baseline.

Every patient except the person described in case 4 received brain radiation therapy after the palliative procedure. One patient (case 3) underwent a course of radiation treatment prior to the operation. Another (case 5) had radiation to her orbit in the dist- tant past after enucleation for retinoblas- toma. Even though previous radiotherapy may be considered a contraindication for third ventriculostomy by some authors, it did not seem to affect the success of third ventriculostomy in our patients. Carcinomatous menin- giomas which could cause complete obstruc- tive hydrocephalus was not grossly evident on examination, on any of the brain imagings, or during endoscopy. How- ever, tumours in contact with CSF space can also cause a communicating hydrocephalus by raising CSF protein which can obstruct distal CSF space and arachnoid granulations.

Our success rate of about 70% (five of seven) for third ventriculostomy in periventric- ular metastatic disease is consistent with the results obtained with third ventriculostomy for adult patients with secondary hydrocephalus.2 This is comparable with the alternative shunting with an implanted shunt which has a first year revision rate as high as...
Results are considered improved if the patient had resolution of symptoms and follow-up imaging showed hydrocephalus improved or resolved.

As 50%, with the highest failure rate in the first few months after shunt placement. The complication rates for both procedures are low. Third ventriculostomy and shunting can potentially cause a stroke, bleeding, ventriculitis, meningitis, a subdural haematoma, CSF leak, diabetes insipidus, and SIADH. However, shunting has additional risks of mechanical malfunction, complications associated with implanting a foreign body, and overdrainage syndrome.

Because third ventriculostomy restores near normal CSF dynamics,1 overdrainage is prevented. The procedure is also minimally invasive and safe. The procedure’s low morbidity, high efficacy, and potentially shorter hospital stay are well suited as a palliative treatment of hydrocephalus for patients with an expected shortened life span. We propose that third ventriculostomy should be offered as a first treatment to patients suffering from obstructive hydrocephalus from unresectable tumours.

Neuronal activity alters local blood flow in the brain tumour adjacent to the activating cortex. Such an interaction between cortical blood flow and tumour blood flow may be of value for evaluating mechanisms of neurological symptoms associated with brain tumours. Neuronal activation causes an increase of regional cerebral blood flow (rCBF) in the activating cortical area.1 Near infrared spectroscopy (NIRS) demonstrates the increase in rCBF during neuronal activity as increases in oxygenated haemoglobin (oxy-Hb) and total haemoglobin (total-Hb) with a decrease in deoxygenated haemoglobin (deoxy-Hb)1,3,4. NIRS is an optical method to measure concentration changes of oxy-Hb, deoxy-Hb, and total-Hb (oxy-Hb+deoxygenated-Hb) in cerebral vessels by means of the characteristic absorption spectra of haemoglobin in the near infrared range.

In the present study, we measured changes of oxygenation and haemodynamics in the brain tumour adjacent to the activating cortex by means of NIRS. We found transient decreases in oxy-Hb and total-Hb in the tumour during neuronal activation, suggesting that the local blood flow of the tumour was decreased by a transient increase of rCBF induced by neuronal activation.

The patient was a 35 year old right handed man who presented with complaints of headache and dizziness. A neurological examination showed no abnormalities and a decline in language functions. A postcontrast CT showed a well defined large enhancing tumour (4×5 cm) compressing the left frontal lobe. Computed tomographic angiography showed that the branches of the left middle cerebral artery supplied the tumour (figure A). The patient underwent a left frontal craniotomy for removal of the tumour; the pathological diagnosis was meningioma. The NIRS measurement was performed before the operation.

We measured haemodynamic changes in the brain tumour during neuronal activation in the left frontal lobe induced by cognitive

**Table 1 Clinical characteristics of patients who underwent third ventriculostomy for obstructive hydrocephalus**

<table>
<thead>
<tr>
<th>Case</th>
<th>Age (y), Sex</th>
<th>Diagnosis</th>
<th>Result*</th>
<th>Postoperative stay in hospital(days)</th>
<th>Survival time (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>70,M</td>
<td>Lung mixed adenocarcinoma and squamous cancer metastasis to thalamus</td>
<td>Improved</td>
<td>17</td>
<td>4</td>
</tr>
<tr>
<td>2</td>
<td>46,F</td>
<td>Ovarian adenocarcinoma metastases to cerebrum and medulla</td>
<td>Improved</td>
<td>9</td>
<td>13</td>
</tr>
<tr>
<td>3</td>
<td>38,F</td>
<td>Breast ductal carcinoma metastases to brainstem and cerebellum</td>
<td>Improved</td>
<td>3</td>
<td>8</td>
</tr>
<tr>
<td>4</td>
<td>75,M</td>
<td>Rectal adenocarcinoma metastasis to cerebellum</td>
<td>Failed</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>5</td>
<td>39,F</td>
<td>Breast adenocarcinoma metastasis to cerebellum</td>
<td>Improved</td>
<td>4</td>
<td>11</td>
</tr>
<tr>
<td>6</td>
<td>60,M</td>
<td>Lung adenocarcinoma metastasis to thalamus</td>
<td>Failed</td>
<td>6</td>
<td>6+†</td>
</tr>
<tr>
<td>7</td>
<td>64,M</td>
<td>Osteophagocarcinoma metastatic to cerebellum</td>
<td>Improved</td>
<td>7+</td>
<td>1+†</td>
</tr>
</tbody>
</table>

*Results are considered improved if the patient had resolution of symptoms and follow up imaging showed hydrocephalus improved or resolved.

†Patient is currently alive.

tasks. We monitored concentration changes of oxy-Hb, deoxy-Hb, and total-Hb, using an NIRO-500 instrument (Hamamatsu Photonic KK, Japan). The optodes were placed at an interoptode distance of 3.5 cm on the left forehead so that the centre of the two optodes was placed over the centre of the tumour. With this interoptode distance of 4 cm, correlations of oxy-Hb and total-Hb measured by NIRS and rCBF measured by PET suggested that the reliable penetration depth of near infrared light into brain tissue is about 1.3 cm, thus the present NIRS measurement area was restricted in the tumour. The patient was seated and had his eyes open during the NIRS measurement. Informed consent was obtained from the Neurosurgical patient.

To activate the left frontal lobe, we used the following four tasks: (1) semantic verbal fluency, which entails naming as many items in a semantic category (for example, animals) as possible; (2) confrontational naming, which involves naming ordinary items presented by the tester; (3) backward digit span, a working memory task which involves reporting of digits (2 to 8) in the reverse order; and (4) reading, which entails reading a short descriptive passage aloud. The speech responses of the patient to the tasks were normal.

Figure B shows an example of changes in NIRS during the naming task. After the beginning of the task, oxy-Hb and total-Hb decreased to negative values during the task, and deoxy-Hb also decreased. These changes returned to the control level gradually after the end of the task. The other tasks also caused similar changes of oxy-Hb, total-Hb, and deoxy-Hb. The rCBF in the left frontal lobe is generally increased by all the tasks used in the present study. Indeed, our NIRS activation study using the cognitive tasks showed increases in oxy-Hb and total-Hb in the left frontal lobe in most normal adults—for example, increases in oxy-Hb and total-Hb—were found in 92.3% of young adult subjects (mean SD) 28.8 (4.4) years during the word fluency task (unpublished data). Therefore, although we could not measure the changes in rCBF in the left frontal lobe of the present patient from our previous studies strongly suggests that the tasks caused an increase in rCBF in the left frontal lobe of the patient.

The decrease in oxy-Hb and total-Hb recorded from the brain tumour indicates a decrease of local blood flow in the tumour because the NIRS measurement area was restricted to the brain tumour. The decreases in oxy-Hb and total-Hb were found only during the tasks; consequently, these changes were probably not due to changes in systemic blood pressure, which can alter tumour blood flow. Based on these assumptions, we suggest that the increase of rCBF in the left frontal lobe induced by the tasks stole the local blood flow of the brain tumour through the cortical branches, leading to the decrease of local blood flow in the tumour.

The present report supports that activity dependent increase in rCBF can steal blood flow from the adjacent tissues including non-activating cortex. Recent NIRS activation studies have shown that cognitive tasks cause decreases in oxy-Hb and total-Hb in the left frontal lobe in some normal subjects; these decreases indicate a decrease in rCBF. Although the physiological mechanisms of the decrease in rCBF during neuronal activity have not yet been elucidated, we hypothesise that a stealing of blood flow is one of the mechanisms. The present report supports this hypothesis.
involve visual association areas and their association pathways. Optic ataxia, gaze apraxia, and simultanagnosia seem to represent a dissociation of visual information from the frontal eye field and dorsal parietal regions.

PARVAIZ A SHAH
A NAPEEF
Division of Neurology, Department of Medicine, Government Medical College and Associated SMHS Hospital, Srinagar, Kashmir, J and K 190001, India
Correspondence to: Dr Parvaiz A Shah, Firdousan-asymmetric, and showed no evidence of lesions were bilateral, widely distributed, in the right hemisphere (figure A). These variably sized lesions were seen in the corpus callosum, basal ganglia, and periventricular white matter regions. The lesions were well demarcated and hypointense relative to normal white matter on T2-weighted and fluid-attenuated inversion recovery images. The lesions were hyperintense on diffusion-weighted imaging and showed diffusion restriction on apparent diffusion coefficient maps, consistent with residual cerebral atrophy.

Rabies is caused by a RNA virus, a member of the Rabdoviridae family, it infects mammals and can be transmitted to humans by contact, generally from an animal excreting the virus in the saliva. Rabies manifests as an acute encephalomyelitis, the development of which is almost invariably fatal. The distinction between rabies and postvaccination encephalitis is difficult and may be helped by antigen detection via a skin biopsy; however, this technique is not available in Vietnam. Paralytic rabies could not be excluded in this patient and hence steroids were not used initially. Steroids have been reported to increase mortality in experimental animals with rabies, and it has been suggested that they may abrogate the immune response to the postexposure vaccine, thus precipitating uncontrollable rabbis.

There are three types of postexposure vaccine in use worldwide. The Simple type (STV) is obtained from inactivated virus prepared on adult animal tissue; it is inexpensive and relatively easy to produce. In India 3 million people receive postexposure courses of STV (phospholipid sheep brain) antirabies vaccine each year. These produce neurological reactions, including postvaccination encephalomyelitis, in up to 1 in 100 courses, with a 3% mortality. Clinical forms include a reversible mononeuropathy multiplex, and meningoencephalitic and encephalomyelitic reactions. Myelin basic protein and related neural proteins from the nervous tissue of the animal on which the virus was cultivated stimulate an autoimmune reaction in the human nervous system.

Tolerance has been improved by the development of the suckling mouse brain vaccine (SMBV). The attenuated virus is cultured on immature mouse brain tissue, which contains little myelin, thus reducing the risk of complications. SMBV is inexpensive (US$1.5 per treatment course) and easily manufactured locally; it is the most widely used postexposure vaccine in Vietnam. Rare neurological reactions do occur with SMBV, Complications of the CNS have been reported to occur after vaccination with an incidence of 1:27000 treated people, with a 22% mortality. The mortality was particularly high (90%) if the patient was extensively CNS involved. The third type of vaccine available is the human diploid cell tissue culture vaccine (HDCV), which is both safe and efficacious. However, the recommended regimen is not affordable in most developing countries.

When we approached the Rabies Laboratory, Ministry of Agriculture and Fisheries, United Kingdom for advice in this case their comment was “why do you use the SMBV, can’t you use another vaccine”. Worldwide about 10 million people each year receive rabies vaccine after exposure; at the Centre for Tropical Diseases we treat 3000 people each year about 10 million people each year receive rabies vaccine after exposure; at the Centre for Tropical Diseases we treat 3000 people each year. Post-exposure rabies prevents a large number of people from becoming infected and can be very effective, but is expensive and relatively easy to produce. In India 3 million people receive postexposure courses of STV (phospholipid sheep brain) antirabies vaccine each year. These produce neurological reactions, including postvaccination encephalomyelitis, in up to 1 in 100 courses, with a 3% mortality. Clinical forms include a reversible mononeuropathy multiplex, and meningoencephalitic and encephalomyelitic reactions. Myelin basic protein and related neural proteins from the nervous tissue of the animal on which the virus was cultivated stimulate an autoimmune reaction in the human nervous system.
Leuкоencephalopathy associated with khat misuse

The leaves of the tree Catha edulis, or khat (also qat and kat) are chewed by a large proportion of the adult population of the Yemen, and throughout Saharan and sub-Saharan Africa. The leaves are also chewed by members of the Yemeni and Somali communities in the United Kingdom. The psychoactive constituents of khat are cathin (1-norisoephrine), cathinone, and cathin (alkaloids with a structure resembling ephedrine and amphetamine) and users report a mild euphoria similar to that of amphetamine. Khat is acknowledged as a precipitant of psychosis and has also been reported to cause cognitive impairment. We report a case in which khat chewing has been associated with a severe and disabling neurological illness.

A 56-year-old man living in the United Kingdom for the past 18 years was admitted to a psychiatric hospital with a 5-week history of progressive confusion and agitation. His family reported that he had been chewing khat in their opinion to excess, every day during that time but had stopped 2 days before admission. There was one previous admission to hospital 9 months previously with khat induced psychosis, from which he recovered without complications within 24 hours. On this occasion, shortly after admission, his conscious level deteriorated abruptly and he was referred for neurological opinion. He was apyrexial and there were no evidence of acute inflammation, and laboratory findings were normal. Tests for HIV antibody, serum angiotensin converting enzyme, white cell enzymes, and serum and urinary porphyrias were negative. Erythrocyte sedimentation rate on admission was 58 mm/h.

Examination of the CSF showed normal opening pressure; sugar 2.7 g/l, glucose 4.3 mmol/l (blood glucose 6.1 mmol/l), and no cells. His initial EEG was abnormal with diffuse slow waves indicative of widespread cerebral disfunction.

A chest radiograph and ultrasound examination of the abdomen were normal. Cranial MRI, although contaminated by movement artefact, showed diffuse abnormality in the deep cerebral white matter of both cerebral hemispheres. Fourteen days after admission he was witnessed to have a single brief adversive seizure with eye and head deviation to the right. The patient was admitted to a rehabilitation unit. His mini mental state examination score and Barthel scores were zero. Feeding by percutaneous gastrostomy was started. A trial of intravenous methylprednisolone (1 g on 3 consecutive days) gave no benefit. Repeated EEGs (on four occasions) showed diffuse slow waves only. A second MRI (3 months after onset of symptom) showed the presence of a continuing diffuse extensive abnormality in the deep white matter of both cerebral hemispheres with marked cortical atrophy. Brain biopsy (via right frontal craniotomy) was performed 3 months after the onset of his illness. There was no evidence of acute inflammation, vasculitis, or infarction. While undergoing rehabilitation there has been slow improvement in his cognitive and locomotor function. After 1 year he is able to open and close his eyes, occasionally verbalise, localise pain, and obey simple commands. His plantar reflexes are fl考核 but he has persistent grasp and palmar reflexes. His nutrition is maintained by gastrostomy and he has an indwelling catheter.

The clinical presentation, EEG, and MRI findings suggest a rapidly progressive leuкоencephalopathy. There are no previous reports of leuкоencephalopathy in association with khat or amphetamine misuse; it has, however, been reported in association with other recreational drugs taken by mouth or inhalation. An alternative for this man’s presentation is a necrotising vasculitis, a well described complication of oral amphetamine misuse. The clinical features, MRI appearance, brain biopsy, absence of haemorrhage, and lack of response to steroids make this unlikely.

The likely precipitant of this man’s illness seems to be the use of khat. A drug screen on admission was negative, and his family denied misuse of other drugs. It remains possible that the sample of khat chewed by this man was contaminated. We are unaware of any previous reports of khat misuse with severe neurological deterioration; previous cases may not have been investigated or reported. In reporting this case our intention is to alert others to a possible complication of the misuse of this drug. Evidence of other cases would provide a powerful argument for the restriction of import and sale of khat.
M-protein, direct and indirect Coombs tests, cryoglobulin, antibodies to mycoplasma, myelin associated glycoprotein, gangliosides (GM1, GD1b, asialo-GM1, GT1b, GQ1b, Gal-C), P-ANCA, and C-ANCA. The CSP was normal. Titre of cold agglutinins was detected at 1:256 at 4°C (normal <1:256). The patient's serum agglutinated adult group O red blood cells, but not O-red blood cells or human cord red blood cells, signifying cold agglutinins with 1 specificity. Immuneleetrophoresis of the eluate confirmed IgM composition.

The initial nerve conduction study showed severe diminution or absence of compound muscle action potentials (CMAPs). Densities of large and small myelinated fibres were markedly decreased. Blood cells. The densities of large and small endoneurium. (bar=30 µm). Some vessels had focal necrosis of the wall. The small vessels in the endoneurium. (bar=20 µm). (B) Most of myelinated fibres are undergoing axonal degeneration. Many macrophages containing myelin debris infiltrate the endoneurium. (bar<80 µm). (A) Sural nerve (toluidine blue staining) showing epineurial vessel surrounded by mononuclear cell infiltrates. Note fibrin deposition (arrow) and necrosis in media. (bar=20 µm). (D) Most of myelinated fibres are undergoing axonal degeneration. Many macrophages containing myelin debris infiltrate the endoneurium. (bar<80 µm).

The hypotheses that the initial nerve conduction block was due to cold agglutinins. This is the first demonstration of vasculitic neuropathy with cold agglutinins. Although the mechanism for neuropathy with cold agglutinins is unknown, mechanisms similar to those in cryoglobulinaemic neuropathy have been postulated. The hypotheses are (1) immunologically mediated demyelination; (2) ischaemic injury secondary to sluggish or agglutination of red blood cells in the vasa nervorum; and (3) associated vasculitis. In the present case, we have confirmed the necrotising vasculitis and probable conduction block. Pathophysiological explanations for association of vasculitis and conduction block may be as follows. Firstly, conduction block may occur as a consequence of nerve ischaemia due to small vessel occlusion. There have been reports of conduction block occurring in vasculitic neuropathy which support this possibility. Secondly, humoral factors including cold agglutinins may induce immunemediated demyelination in the peripheral nervous system. Taken together, neuropathy with cold agglutinins may involve immunologically mediated demyelination, microcirculation occlusion, and vasa nervorum vasculitis. The diversity of pathomechanisms may come from the difference target antigens recognised by cold agglutinins. Plasmapheresis proved effective in all cases. These findings strongly suggest that humoral factors including cold agglutinins may play an important part in the induction of neuropathy with cold agglutinins. We recommend plasmapheresis as first choice treatment for neuropathy associated with cold agglutinins.

We thank Dr Gerard Salazar for critical reading of the manuscript, Ms M Teshima and N Hirata for their technical assistance, Dr S Kusunoki (Department of Neurology, Institute for Brain research, University of Tokyo) for analyses of antibodies to gangliosides, and Mr H Moung (Division of Blood Transfusion Medicine, University of Kagoshima) for characterization of cold agglutinin.
The cholinergic hypothesis of Alzheimer’s disease: a review of progress

I read with interest the review of Francis et al regarding the progress of the cholinergic hypothesis of Alzheimer’s disease.1 They mentioned that donepezil produced improvement or no deterioration in more than 80% of patients, and that such responses should be viewed positively considering the progressive, degenerative nature of the disease. Various donepezil manufacturer’s medical representatives presenting data from a clinical study2 also commonly use this statement. However, this only partially reveals the truth. In fact, the same study produced improvement or no deterioration in 59% patients on placebo. I think that the beneficial effect of donepezil in particular clinical trials should always be critically reviewed in comparison with placebo. In addition, as both 24 week placebo controlled donepezil trials performed so far excluded patients with behavioural disturbances, my impression is that the positive effect of donepezil on the symptoms of behavioural disturbances still remains controversial. In fact there are reports that donepezil might induce behavioural disturbances in patients with Alzheimer’s disease.3 Therefore, I would be extremely cautious about prescribing donepezil to patients with Alzheimer’s disease accompanied by behavioural disturbances.

Finally, donepezil was never investigated in a 36 week randomised double blind study as was mentioned in the review. The authors are probably referring to the randomised 24 week double blind placebo controlled trial with an additional 6 week single blinded placebo phase.

T BABIC
Department of Neurology, Medical School University of Zagreb, Kliševica 12, 10000 Zagreb, Croatia.
Telephone 00385 1 217280, fax 00385 1 217280, email tomaslasc.babic@zg.htz.hr

The authors reply: We thank Professor Babic for the letter, which raises several interesting points. We agree that it may be more helpful to put the results attributed to treatment with donepezil in the context of the placebo response. In general, looking at this as a class effect in relation to several compounds, the picture emerging is that about twice as many people obtain a response to active treatment as to that with placebo. The high placebo response is a common factor in most studies in this field and is worthy of some explanation in its own right. Although it seems that these studies compare drug treatment with that of a placebo (one treatment against no treatment), the reality is that it is a comparison of patients receiving two treatments against other patients who are receiving one form of treatment. The additional treatment regime is, of course, the care and attention that they receive by being part of the clinical study, which often seems to have an impact, not just on the patient but also on their main carer or carers.

As far as behavioural disturbances are concerned, however, our review was making the point that evidence in support from clinical trials to suggest that cholinomimetics as a whole may have a beneficial effect on some non-cognitive behavioural symptoms. This has now been reported for at least two cholinesterase inhibitors, and two muscarinic agonists.4 In particular, a clear link is emerging between psychotic symptoms and cholinergic dysfunction. Thus, Bodick et al have shown that the M3/M4 agonist donepezil causes a dose-dependent reduction in hallucinations, agitation, and delusions in a 6 month randomised double blind placebo controlled, parallel group trial. In addition, Cummings and Kaufer have shown that the cholinesterase inhibitor tacrine also reduces or abolishes hallucinations in Parkinson’s disease. A cholinesterase inhibitor, metrifonate, was also shown to reduce the number of hallucinations in a 26 week randomised, double blind, placebo controlled safety and efficacy study in patients with Alzheimer’s disease. Further support for a link between choline and psychosis derives from postmortem data showing that the activity of choline acetyltransferase in the temporal cortex of patients with Lewy body dementia was lower in those patients with hallucinations than in patients without this feature. Finally, in animals the partial M3/M4 agonist (3R,6R)-6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane has shown a preclinical profile suggestive of antipsychotic efficacy5 and that the psychomimetic NMDA receptor antagonist ketamine (when administered at subanesthetic doses) reduced brain concentrations of acetylcholine. Thus, on the basis of both clinical and preclinical data, a clear rationale is emerging for prescribing cholinomimetic agents for treating the non-cognitive behavioural symptoms associated with dementia, particularly psychosis.

Professor Babic is also correct in identifying two of the studies referred to as the 30 week randomised multicentre placebo controlled parallel group studies, which included a 24 week double blinded treatment phase.

We are grateful to your correspondent for providing us with the opportunity to clarify these points.

PAUL T FRANCIS
Neuroscience Research Centre, GKT School of Biomedical Science, King’s College London, London
SE1 9RT, UK

ALAN M PALMER
MICHAEL SNAPE
Cerebrus Pharmaceuticals Ltd, Wimersh, Ribingham, RG41 5UA, UK

GORDON K WILCOCK
Department of Care of the Elderly, Frensham Hospital, Farnham, Surrey, GU10 6EY, UK

BOOK REVIEWS


The neuropathies of diabetes are common (as the chapters in this book repeatedly remind us) and can be very disagreeable. Symptomless neuropathy underlies foot ulceration and sepsis as the commonest clinical consequence of diabetic neuropathy but those who experience the unpleasant disorders range from exceptionally severely painful to the whole range of problems resulting from autonomic failure. This book comprehensively covers every aspect of the subject, systematically (and at times exhaustively) from its epidemiology and pathogenesis (exhaustingly) to structural, functional, and clinical problems and their treatment. Most of the authors are well known in the field and their accounts are up to date and authoritative.

Unfortunately, struggle as they might, all authorities have difficulty in defining what they mean by diabetic neuropathy, in regard, understanding of this complication both in clinical and pathological terms, as well as with regard to treatment, lags far behind that of the other classic diabetic complications—nephropathy and retinopathy. Even its classification presents problems and attempts to do so are found in four different chapters, describing four classifications. Repetition is an unfortunate feature of this book and—quite apart from the confusion over classification—aspects of pathogenesis, structural changes, epidemiology, diagrams, and some reference to treatment (for example, that of pain) appear repeatedly in different chapters in greater or lesser detail.

This is certainly a book for the specialist and not at all (as the preface suggests) for the family practitioner. There are good reviews of nerve structure, causation, and treatment of painful neuropathies and focal neuropathies. The comprehensive survey of the Diabetes Control and Complications Trial (DCCT) shows in detail the only treatment which is truly effective (diabetic control), and the lengthy description of aldose reductase inhibitor trials establishes that, even after more than two decades of investigation, further trials are still needed.

Clinical evaluation of somatic and autonomic neuropathies are useful and also, to some extent, comprehensive but lack specificity—that is, normal values for simple tests are difficult to find. The huge subject of the diabetic foot is covered in these chapters and “the impact of micro and macrovascular disease” is compressed into the last nine pages of the book.

The bibliography is important and often very up to date with references ranging from 33 to 283 per chapter.

If this book is at times confusing, this reflects the confusion regarding the nature and treatment of the diabetic neuropathies as much as the overlap and repetition found in its different chapters. It is a book of reference for the specialist who will be well served by the comprehensiveness of some of its reviews and their assembly of the appropriate literature.

PETER WATKINS


The quest for a means of accurate localisation of structures during neurosurgery has taxed the minds of clinicians from early in the history of the speciality, starting with Zernov’s encephalometer more than a century ago. Just as the solution to the mariners’ problem of determining longitude from which it partly takes its name, neuronavigation (“the surgeon’s sextant”) has relied on the advent of new technologies to provide solutions to an age old puzzle.

**Advances In Neuronavigation begins** by tracing the history of stereotaxis from a Cartesian coordinate system devised by Clarke and Horsley at the beginning of this century, through ventriculography, stereotactic brain atlases, and CT/MRI frame based stereotaxis. The final part of the first section discusses the roots of image guided frameless stereotaxis through the integration of high speed graphics computers, informatics, biotechnology, and robotics.

The remainder of the text is divided into four sections. The first concerns the creation of maps from CT, MRI, MRA, PET, and various types of functional imaging. The following section discusses clinical applications of stereotaxis, beginning with different authors’ experiences of their own favoured frames, the biopsy of difficult lesions such as those in the brainstem or posterior fossa, and finally experience with different image guidance systems and their integration with the operating microscope and endoscope. There then follows a series of chapters devoted to radiosurgery, and to image guidance in epilepsy and functional surgery. The final section is entitled **Frontiers in Neurosurgical Navigation** and considers, among other topics, intraoperative MRI, telepresence in neurosurgery, and robotics.

The incorporation of new technology is likely to alter surgical practice radically over the coming decade and equipment that seemed at the cutting edge of technology only a few years ago, such as the mechanical arm, has already passed into near obsolescence at a bewildering rate. This volume provides an excellent account of the developments which have occurred in neuronavigation, and a thought provoking insight into the wider applications of equipment of which many of us use only a fraction of the potential capability. The title of the book should perhaps have included the word cranial, as there is almost no discussion of the impact that this technology has had in surgery of the spine. This aside it is an excellent book although, like the technology it chronicles, one which is likely to date quite rapidly.

ROBERT MACFARLANE


The title and back cover of the latest addition to Neurology Lite texts contains the usual proclamations. “Concise, key topics, revision aid, essential, review...” the well trailed soundbites demanded by the consumer in the increasingly competitive market of “read less - learn more” books. This book, however, is unusual and distinct. Unlike many rivals it is not an A5 facsimile of a superior A3 reference tome. Brevity, so essential to the success of an overview work, has sacrificed neither clarity nor clinical relevance. The strength of Key Topics in Neurology owes much to the author’s ability to negotiate skilfully the compromises necessary for a successful distillation of a large and complex field. He has not shied from wholesale culling of neurological ballast. The allied ability to distil and highlight the salient and relevant from the obscure and historical allows this book to be surprisingly thorough in its coverage and topicality. There is sufficient up to date information on most areas of neurology such that this book would be useful for specialist registrars albeit without the detail or embellishment they seek. In terms of the aims of this book such observations must be regarded as complimentary.

My limited criticisms relate to details of layout and presentation. I found the exclusive alphabetical arrangement of chapters mildly disorientating in that, for example, History taking in Neurology is to be found at p 131. Similarly, the absence of diagrams and tables is an unexpected omission as I would imagine that this would have complemented the overall style of the book. These are minor gripes of what in print largely matches the sleeve hype and with a price tag of just £27.50 the book will be welcomed by undergraduates through to specialist registrars.

SIDDHARTHAN CHANDRAN

**Readers may be interested in:**


